Ocugen Picks Jubilant HollisterStier As Manufacturing Partner For Vaccine Candidate Covaxin

(RTTNews) - Biopharmaceutical company Ocugen, Inc. (OCGN) announced Tuesday that it has selected Spokane, Washington-based Jubilant HollisterStier as its manufacturing partner for Covaxin to prepare for potential commercial manufacturing of Covaxin for the US and Canadian markets.

Covaxin, India's COVID-19 vaccine by Bharat Biotech, is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). Covaxin is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform.

Covaxin continues to show strong results in all the studies conducted to date including a vaccine efficacy rate of 78% overall efficacy and 100% in severe COVID-19 disease, including hospitalizations, in second interim results of Bharat Biotech's Phase 3 clinical trial.